Preclinical specificity & activity of a fully human 41BB-expressing anti-CD19 CART- therapy for treatment-resistant autoimmune disease.
Peng BJ, Alvarado A, Cassim H, Guarneri S, Wong S, Willis J, SantaMaria J, Martynchuk A, Stratton V, Patel D, Chen CC, Li Y, Binder GK, Dryer-Minnerly R, Lee J, Basu S.
Peng BJ, et al.
Mol Ther Methods Clin Dev. 2024 May 20;32(2):101267. doi: 10.1016/j.omtm.2024.101267. eCollection 2024 Jun 13.
Mol Ther Methods Clin Dev. 2024.
PMID: 38883975
Free PMC article.